Deciphera Pharmaceuticals

Partner Level
Company Headquarters
Waltham, MA
Visit Site

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK® is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit and follow us on LinkedIn and Twitter (@Deciphera).


Patient Support Program

Deciphera AccessPoint
1-833-4DACCES (1-833-432-2237) Monday–Friday 8AM–8PM ET
1-833-DCPH-FAX (1-833-327-4329)
Email to schedule a call back

© 2021 FLASCO | Premium Website Design by The HDG